Novo Holdings

Novo Holdings today announced its participation in a €80 million Series A financing round for Antag Therapeutics, a Danish biopharmaceutical company developing innovative therapies targeting obesity and cardiometabolic diseases.   Founded in 2017 and headquartered in Copenhagen, Denmark, Antag works to advance next-generation treatments for obesity, focusing on new therapeutic strategies to complement existing GLP-1 therapies.   The €80 million Series A round was led by Versant Ventures, with participation from SR One Capital Management, Dawn Biopharma, Pictet Group, Longview Ventures, and the Export and Investment Fund of Denmark (EIFO), alongside founding investor Novo Holdings.

Johan Hueffer, Senior Partner at Novo Holdings, spoke to CNBC today about our focus on innovation in planetary health, as evident by our recent investments in aquaculture leaders Benchmark Genetics and Stingray Marine Solutions AS.   Watch the interview here:

Novo Holdings participates in the oversubscribed $135 million series B financing in Adcendo, a biotech company focused on the development of first-in-class antibody-drug conjugates (ADCs) for the treatment of cancers with a high unmet medical need.   The financing round was led by TCGX, with participation from new investors TPG, OrbiMed, VENROCK HEALTHCARE CAPITAL PARTNERS LP, Surveyor Capital, and Logos Capital, as well as all existing investors, including RA Capital Management, Novo Holdings, Pontifax Venture Capital, Dawn Biopharma, HealthCap, Gilde Healthcare and Ysios Capital.   Proceeds from the fundraise will be used to advance, broaden, and accelerate the development of Adcendo’s ADC pipeline.

Novo Holdings today announced that it has agreed to acquire the Norwegian fish genetics company Benchmark Genetics from Benchmark Holdings plc for an enterprise value of up to £260 million.   Headquartered in Bergen, Norway, Benchmark Genetics is a leader in salmonid genetics, providing eggs and other genetic services to both traditional and land-based farmers. By combining its long-established breeding programs and the latest genomic tools, Benchmark Genetics helps aquaculture producers increase quality, yield, health, and animal welfare.

Our REPAIR Impact Fund supports companies such as LimmaTech Biologics AG, whose vaccine candidates target life-threatening bacterial infections where resistance is rising. On the occasion of World AMR Awareness Week, we are pleased to highlight our support for LimmaTech to advance its pipeline and bring much-needed solutions to those facing serious, hard-to-treat infections. #WAAW #WAAW2024

As part of World Antimicrobial Awareness Week, Novo Holdings is highlighting its commitment to addressing the antimicrobial resistance (AMR) crisis through the REPAIR Impact Fund, backing innovative solutions to confront this urgent global health issue.   We are sharing a powerful documentary co-produced by the BBC and the AMR Action Fund. This film delves into the growing threat of AMR and highlights the essential work of scientists, doctors, and specialists dedicated to finding innovative approaches and advancing research to protect future generations. Watch the film to learn more about this pressing global health issue and the strides being made to address it. #WAAW #WAAW2024

Novo Holdings was named Venture Capital Firm of the Year at the European Lifestars Awards - Celebrating Life Science Leaders 2024. We would like to thank LSX for this recognition and for organising the event.    We would also like to extend our congratulations to the Novo Holdings portfolio companies honoured at the Lifestars Awards for their achievements:   - Series A finance of the year: Myricx Bio  - Private Company CEO of the year: Barbara Angehrn Pavik, Asceneuron SA   #LifestarsAwards #JefferiesHealthcare 

See you at Jefferies?    Novo Holdings will be attending the Jefferies Healthcare Conference in London. The conference provides a valuable opportunity to connect, and we look forward to meeting you.   #JefferiesHealthcare

Novo Holdings announces that it has co-led a $181.4 million Series D financing in Alentis Therapeutics.   Alentis is developing first-in-class CLDN1-targeted antibody-drug conjugates (ADCs) to treat solid tumours. The funding will support the development of Alentis’s ADC pipeline, including Phase 1/2 trials for its lead candidates, expected to begin in 2025.

We are looking for an Executive Assistant to join our People & Organisation team. As our Executive Assistant, your role will be to support our Chief People Officer and play a pivotal role in coordinating and supporting the People & Organisation’s team, consisting of 15 people globally.